Phaseline

Targets › SELENOP

SELENOP (Selenoprotein P): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Cardiovascular, Psychiatry; next expected readout Apr 2027.

Might be responsible for some of the extracellular antioxidant defense properties of selenium or might be involved in the transport of selenium. May supply selenium to tissues such as brain and testis. (UniProt, P49908)

Open in Phaseline: the race on SELENOP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Tor Biering-SørensenSelenium
Cofactor for selenoproteins including glutathione peroxidase; antioxidant support
SELENOPPhase 3Heart FailureDec 2028
Skane University HospitalSelenium (Bio-SelenoPrecise)
Selenium supplementation; trace element cofactor for selenoproteins involved in antioxidan
SELENOP, SELENOWPhase 3Heart FailureMar 2030
First Affiliated Hospital of Chongqing Medical Universityselenium yeast supplementation
selenium cofactor for selenoprotein synthesis
SELENOP, SELENOK, SELENOW, SELENOFPhase 2Depression - Major Depressive DisorderApr 2027

Conditions

Heart Failure (2) Depression - Major Depressive Disorder (1)

Modalities

small molecule (1)

Companies

Skane University Hospital (1) Tor Biering-Sørensen (1) First Affiliated Hospital of Chongqing Medical University (1)

Related targets

SELENOW (2) SELENOK (1) SELENOF (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.